Genmab, GCT3013-03, Ph 1/2b, Open-Label, GEN3013, Leukemia/Richter's Syndrome

What is the Purpose of this Study?

Objectives and Endpoints: Dose Escalation Monotherapy Cohorts (R/R CLL): Primary Objective: Identify the RP2D and the MTD of epcoritamab Evaluate the safety and tolerability of epcoritamab Secondary: Characterize the PK properties of epcoritamab Evaluate immunogenicity of epcoritamab Assess the preliminary antitumor activity of Epcoritamab Objectives and Endpoints: Expansion Monotherapy (R/R CLL [Arm 1] and RS [Arm 2A]) Primary: Assess the preliminary efficacy of epcoritamab Secondary: Evaluate the preliminary efficacy of epcoritamab Evaluate the safety and tolerability of epcoritamab Establish the PK profile of epcoritamab Assess MRD status in peripheral blood and bone marrow Evaluate immunogenicity of epcoritamab Objectives and Endpoints: Dose Escalation Venetoclax Combination Therapy (R/R CLL) Primary: Identify the RP2D and the MTD of epcoritamab when coadministered with venetoclax 400 mg Evaluate safety and tolerability of the combination of epcoritamab and venetoclax Secondary: Assess the preliminary antitumor activity of epcoritamab in combination with venetoclax Evaluate other efficacy measures of epcoritamab in combination with venetoclax Assess PK profile of epcoritamab in combination with venetoclax Assess MRD status in peripheral blood and bone marrow Evaluate immunogenicity of epcoritamab when coadministered with venetoclax Objectives and Endpoints: Expansion Venetoclax Combination Therapy in R/R CLL (Arm 3) Primary: Assess the preliminary antitumor effect of epcoritamab in combination with venetoclax Secondary: Evaluate other efficacy measures of epcoritamab in combination with venetoclax Evaluate the safety and tolerability of epcoritamab in combination with venetoclax Establish the PK profile of epcoritamab in combination with venetoclax Assess MRD status in peripheral blood and bone marrow Evaluate immunogenicity of epcoritamab when coadministered with venetoclax Objectives and Endpoints: Expansion Lenalidomide Combination Therapy in RS (Arm 2B) and R-CHOP Combination Therapy in RS (Arm 2C) Primary: Assess the preliminary antitumor effect of epcoritamab in combination with lenalidomide (Arm 2B) or R-CHOP (Arm 2C) Secondary: Evaluate other efficacy measures of epcoritamab in combination with lenalidomide (Arm 2B) or R-CHOP (Arm 2C) Evaluate the safety and tolerability of epcoritamab in combination with lenalidomide (Arm 2B) or R-CHOP (Arm 2C) Establish the PK profile of epcoritamab in combination with lenalidomide (Arm 2B) or R-CHOP (Arm 2C) Assess MRD status in peripheral blood and bone marrow Evaluate immunogenicity of epcoritamab when coadministered with lenalidomide (Arm 2B) or R-CHOP (Arm 2C)

Eligibility

1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
2. Evidence of CD20 positivity in a sample representative of the disease at Screening.
3. Acceptable hematology parameters and organ function based on baseline bloodwork.
4. Life expectancy \>3 months on standard of care (SOC) for CLL, \>3 months for RS.

Key Inclusion Criteria

1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
2. Evidence of CD20 positivity in a sample representative of the disease at Screening.
3. Acceptable hematology parameters and organ function based on baseline bloodwork.
4. Life expectancy \>3 months on standard of care (SOC) for CLL, \>3 months for RS.
5. For R/R CLL arms - Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria.
6. For R/R CLL monotherapy arms - Received at least 2 prior lines of systemic anti-neoplastic therapy including a Bruton's tyrosine kinase (BTK) inhibitor or at least 1 prior line of systemic antineoplastic therapy, including treatment with (or intolerance of) a covalent BTK inhibitor (cBTKi) and a B-cell lymphoma 2 (BCL-2) inhibitor.
7. For all RS arms - Have tumor biopsy-proven CD20+ Diffuse large B-cell Lymphoma (DLBCL) and a clinical history of CLL/SLL.
8. For all RS arms - Must have measurable disease by fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) or magnetic resonance imaging (MRI) scan.
9. For all RS arms - Must provide mandatory formalin-fixed, paraffin-embedded (FFPE) tumor biopsy sample.
10. For RS - monotherapy arm: Deemed as ineligible for chemoimmunotherapy at investigator's discretion or participant who refuses to receive intensive chemotherapy
11. For RS - lenalidomide combination therapy arm
* Deemed as ineligible for chemoimmunotherapy at the investigator's discretion, or participant who refuses to receive intensive chemotherapy.
* Eligible for treatment with lenalidomide.
* Must be willing to use contraception and adhere to the Lenalidomide Pregnancy Risk Minimization Plan
* A woman must agree not to breastfeed a child during treatment and for at least 28 days after discontinuation from study.
12. For RS - R-CHOP combination Therapy Arm -
* Eligible for treatment with R-CHOP.
* Females of childbearing potential must use highly effective contraceptive measures while taking R-CHOP and for 12 months after stopping treatment.
* A woman must agree not to breastfeed a child during treatment or until 12 months after last treatment.
13. For R/R CLL - venetoclax combination Therapy arm - after receiving at least 1 prior line of systemic antineoplastic therapy.
* Presence of measurable disease.
* Must take prophylaxis for tumor lysis syndrome (TLS).
14. For R/R CLL pirtobrutinib combination Therapy arm:
* Must have active CLL/SLL disease requiring treatment per iwCLL 2018 criteria.
* Presence of measurable disease.
* Previous treatment with at least one and a maximum 3 prior lines of therapy including a cBTKi.
* Diagnosis of CLL/SLL that met published iwCLL criteria.
15. Non-US Participants Only - Participants with TN HR CLL - Pirtobrutinib Combination Therapy Expansion:
* Diagnosis of CLL/SLL that met published iwCLL criteria 2018.
* Must have active CLL/SLL disease that needs treatment per iwCLL
* Must take prophylaxis for TLS based on their TLS risk evaluation upon initiation of trial drug.
* Must have one or more high-risk features.
* Presence of measurable disease.

Key Exclusion Criteria

1. Received prior treatment with a CD3×CD20 bispecific antibody.
2. Received any prior allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation.
3. Received chimeric antigen receptor (CAR) T-cell therapy within 100 days or an investigational drug within 4 weeks, prior to first dose of trial drug.
4. Autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy.
5. Received vaccination with live vaccines within 28 days.
6. Clinically significant cardiac disease.
7. Known current malignancy other than inclusion diagnosis.
8. Has had major surgery within 4 weeks.
9. Known history of human immunodeficiency virus (HIV).
10. For R/R CLL arms - Any history of RS or evidence indicating a potential Richter's transformation.
11. For R/R CLL - Venetoclax Combination Therapy arm: received venetoclax within 24 months prior to beginning venetoclax ramp-up for this trial or has progressed on venetoclax treatment.
12. For all RS arms - Diagnosis of Richter's syndrome not of the DLBCL subtype such as Hodgkin's lymphoma, prolymphocytic leukemia.
13. RS - Lenalidomide Combination Therapy and RS Monotherapy Arms - received more than 2 prior lines of therapy for RS.
14. R/R CLL - Pirtobrutinib Combination Therapy Arm - Prior exposure to a non-covalent (reversible) BTK inhibitor or a BTK degrader.
15. Pirtobrutinib Combination Therapy Expansion Arms:
* History of bleeding disorders or participants requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist
* Require continuous treatment with or have received strong cytochrome P450 (CYP) 3A inhibitors or strong/moderate CYP3A inducers within 4 to 5 half-lives or 14 days prior to the first dose of pirtobrutinib.

Show less

Where can I participate?

CS Cancer at Cedars-Sinai Medical Center : Emilie Douine-Barthelemy

More about this Clinical Trial

What is the full name of this clinical trial?

GCT3013-03: A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome *

Study Details

Disease Type/Condition

Lymphoid Leukemia

Principal Investigator

Darrah, Justin

Co-Investigators

Akil Merchant, David Oveisi, Joshua Sasine, Noah Merin, Robert Vescio, Ronald Paquette

Age Group

Adult

Phase

I/II

IRB Number

Study00002920

ClinicalTrials.gov ID

NCT04623541

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

Name

Emilie Douine-Barthelemy

emilie.douine-barthelemy@cshs.org